EA201390543A1 - Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат - Google Patents
Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетатInfo
- Publication number
- EA201390543A1 EA201390543A1 EA201390543A EA201390543A EA201390543A1 EA 201390543 A1 EA201390543 A1 EA 201390543A1 EA 201390543 A EA201390543 A EA 201390543A EA 201390543 A EA201390543 A EA 201390543A EA 201390543 A1 EA201390543 A1 EA 201390543A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- biomarkers
- concentration
- acetate
- glatiramer acetate
- gletiramer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/55—IL-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Способ лечения объекта-человека, страдающего рассеянным склерозом или перенесшего однократный клинический приступ, соответствующий рассеянному склерозу, с помощью фармацевтической композиции, включающей глатирамер ацетат и фармацевтически приемлемый носитель, причем способ включает стадии определения того, отвечает ли объект-человек на глатирамер ацетат, путем оценки биомаркера, выбранного из группы, состоящей из концентрации IL-17, концентрации TNF-α, концентрации IL-2 и концентрации IFN-γ или их комбинации в крови объекта-человека, и стадии введения объекту-человеку фармацевтической композиции, включающей глатирамер ацетат и фармацевтически приемлемый носитель, только если объект-человек идентифицирован как отвечающий на глатирамер ацетат.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39196810P | 2010-10-11 | 2010-10-11 | |
PCT/US2011/055588 WO2012051106A1 (en) | 2010-10-11 | 2011-10-10 | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201390543A1 true EA201390543A1 (ru) | 2013-09-30 |
EA025780B1 EA025780B1 (ru) | 2017-01-30 |
Family
ID=45938670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201390543A EA025780B1 (ru) | 2010-10-11 | 2011-10-10 | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
Country Status (15)
Country | Link |
---|---|
US (3) | US8709433B2 (ru) |
EP (1) | EP2627669B1 (ru) |
JP (2) | JP2013541010A (ru) |
KR (1) | KR20140019296A (ru) |
AU (1) | AU2011313842B2 (ru) |
BR (1) | BR112013008573A2 (ru) |
CA (1) | CA2814500A1 (ru) |
EA (1) | EA025780B1 (ru) |
ES (1) | ES2602977T3 (ru) |
IL (1) | IL225118A (ru) |
MX (1) | MX347871B (ru) |
NZ (2) | NZ703122A (ru) |
PL (1) | PL2627669T3 (ru) |
PT (1) | PT2627669T (ru) |
WO (1) | WO2012051106A1 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2760802C (en) | 2009-08-20 | 2016-01-12 | Ety Klinger | Low frequency glatiramer acetate therapy |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
NZ703122A (en) | 2010-10-11 | 2016-06-24 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
WO2013055683A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
EP2971173A4 (en) | 2013-03-14 | 2016-11-23 | Mylan Inc | GLATIRAMERATE ACETATE POWER TEST BY MRM RESPONSE BIOMARKERS |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
AU2014340010B2 (en) | 2013-10-24 | 2021-05-27 | Mylan Inc. | Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
US20160213633A1 (en) * | 2015-01-28 | 2016-07-28 | Teva Pharmaceutical Industries, Ltd. | Method of inducing anti-glatiramer acetate antibody response |
CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
US5800808A (en) | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
CA2337688C (en) | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
AU766498B2 (en) | 1998-07-23 | 2003-10-16 | President And Fellows Of Harvard College, The | Synthetic peptides and methods of use for autoimmune disease therapies |
HU229720B1 (en) | 1998-09-25 | 2014-05-28 | Yeda Res & Dev | Copolymer 1 related polypeptides for us as molecular weight markers and for therapeutic use |
US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
CA2355400A1 (en) | 1998-11-12 | 2000-05-18 | Yeda Research And Development Co., Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd |
WO2005046719A1 (en) | 2003-11-12 | 2005-05-26 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
US6844314B2 (en) | 2000-01-20 | 2005-01-18 | Yeda Research Development Co., Ltd. | Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
CA2400374A1 (en) | 2000-02-18 | 2001-08-23 | Adrian Gilbert | Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
CA2411536A1 (en) | 2000-06-05 | 2001-12-13 | V. Wee Yong | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
IL150801A0 (en) | 2000-06-07 | 2003-02-12 | Yeda Res & Dev | The use of copolymer 1 and related peptides and polypeptides for protecting central nervous system cells from glutamate toxicity |
WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
ES2349033T3 (es) | 2001-12-04 | 2010-12-22 | Teva Pharmaceutical Industries, Ltd. | Procedimientos para la medida de la actividad del acetato de glatiramer. |
MXPA04005537A (es) | 2001-12-06 | 2004-11-01 | Yeda Res & Dev | Vacuna y metodo para el tratamiento de enfermedades de las neuronas motoras. |
EP1565486A2 (en) | 2002-11-13 | 2005-08-24 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
CN1758922A (zh) | 2003-01-07 | 2006-04-12 | 耶达研究及发展有限公司 | 用于治疗性免疫接种的含共聚物1的滴眼用疫苗 |
NZ569331A (en) | 2003-01-21 | 2010-08-27 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
EP1603530A1 (en) | 2003-03-04 | 2005-12-14 | Teva Pharmaceutical Industries Limited | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
SI1638589T1 (sl) | 2003-05-14 | 2014-07-31 | Teva Pharmaceutical Industries Ltd. | Kombinirana terapija z glatiramer acetatom in mitoksantronom za zdravljenje multiple skleroze |
WO2005007673A2 (en) * | 2003-07-03 | 2005-01-27 | Rush University Medical Center | Immunogenic peptides |
WO2005030955A1 (ja) | 2003-09-29 | 2005-04-07 | Chugai Seiyaku Kabushiki Kaisha | Nk細胞に発現するタンパク質 |
NZ546379A (en) | 2003-10-31 | 2010-04-30 | Teva Pharma | Nanoparticles for drug delivery |
AU2005218625A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
CA2579038A1 (en) * | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
ATE536363T1 (de) | 2004-09-09 | 2011-12-15 | Teva Pharma | Verfahren zur herstellung von mischungen von trifluoroacetyl-glatirameracetat bei verwendung von hydrobromsäure |
SI1797109T1 (sl) | 2004-09-09 | 2016-07-29 | Yeda Research And Development Co., Ltd. | Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe |
AU2005302500B2 (en) | 2004-10-29 | 2008-11-27 | Sandoz Ag | Processes for preparing glatiramer |
KR20070108388A (ko) | 2005-02-02 | 2007-11-09 | 테바 파마슈티컬 인더스트리즈 리미티드 | 가수소분해를 이용한 폴리펩타이드의 혼합물의 제조방법 |
US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
PT1848415E (pt) | 2005-02-17 | 2013-06-27 | Teva Pharma | Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla |
US20060240463A1 (en) | 2005-04-25 | 2006-10-26 | Rappaport Family Institute For Research In The Medical Sciences | Markers associated with the therapeutic efficacy of glatiramer acetate |
US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
SI1929297T1 (sl) * | 2005-09-29 | 2013-06-28 | Caprion Proteomics Usa, Llc | Bioloĺ ki oznaäśevalci pri multipli sklerozi in metode za njihovo uporabo |
US20070161566A1 (en) | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
EP2143728A1 (en) | 2006-07-05 | 2010-01-13 | Momenta Pharmaceuticals, Inc. | Improved process for the preparation of copolymer-1 |
EP2171044A1 (en) * | 2007-06-25 | 2010-04-07 | Vertex Pharmceuticals Incorporated | Th-17 cells |
EP2111105A4 (en) | 2007-11-28 | 2011-05-04 | METHOD FOR DELAYING THE BEGINNING OF A CLINICALLY DEFINED CLINIC SCLEROSIS | |
EP2113560A1 (en) * | 2008-04-28 | 2009-11-04 | TXCell | Compositions for treating an arthritic condition |
US20100167421A1 (en) * | 2008-09-19 | 2010-07-01 | University Of Utah Research Foundation | Methods for identification and prediction of multiple sclerosis disease and therapy response |
US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
EP2275086B1 (en) | 2009-07-15 | 2012-03-14 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
CA2760802C (en) * | 2009-08-20 | 2016-01-12 | Ety Klinger | Low frequency glatiramer acetate therapy |
US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
NZ703122A (en) | 2010-10-11 | 2016-06-24 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
WO2013055683A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
US20150328277A1 (en) | 2012-12-21 | 2015-11-19 | Teva Pharmaceutical Industries, Ltd. | Oral transmucosal delivery of glatiramer acetate |
CN104869983A (zh) | 2012-12-21 | 2015-08-26 | 泰华制药工业有限公司 | 醋酸格拉替雷的透粘膜给药 |
CN105228651A (zh) | 2013-01-04 | 2016-01-06 | 泰华制药工业有限公司 | 表征醋酸格拉替雷相关的药品 |
JP2016512552A (ja) | 2013-03-12 | 2016-04-28 | テバ ファーマシューティカル インダストリーズ リミティド | リツキシマブ導入療法とその後の酢酸グラチラマー療法 |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2011
- 2011-10-10 NZ NZ703122A patent/NZ703122A/en not_active IP Right Cessation
- 2011-10-10 EA EA201390543A patent/EA025780B1/ru not_active IP Right Cessation
- 2011-10-10 ES ES11833199.0T patent/ES2602977T3/es active Active
- 2011-10-10 KR KR1020137012245A patent/KR20140019296A/ko not_active Application Discontinuation
- 2011-10-10 EP EP11833199.0A patent/EP2627669B1/en active Active
- 2011-10-10 AU AU2011313842A patent/AU2011313842B2/en not_active Ceased
- 2011-10-10 JP JP2013533913A patent/JP2013541010A/ja not_active Withdrawn
- 2011-10-10 PL PL11833199T patent/PL2627669T3/pl unknown
- 2011-10-10 BR BR112013008573A patent/BR112013008573A2/pt not_active IP Right Cessation
- 2011-10-10 WO PCT/US2011/055588 patent/WO2012051106A1/en active Application Filing
- 2011-10-10 PT PT118331990T patent/PT2627669T/pt unknown
- 2011-10-10 CA CA2814500A patent/CA2814500A1/en not_active Abandoned
- 2011-10-10 NZ NZ609938A patent/NZ609938A/en not_active IP Right Cessation
- 2011-10-10 MX MX2013003929A patent/MX347871B/es active IP Right Grant
- 2011-10-10 US US13/269,913 patent/US8709433B2/en not_active Expired - Fee Related
-
2013
- 2013-03-07 IL IL225118A patent/IL225118A/en not_active IP Right Cessation
-
2014
- 2014-04-11 US US14/250,955 patent/US9063153B2/en not_active Expired - Fee Related
-
2015
- 2015-05-07 US US14/706,843 patent/US9625473B2/en not_active Expired - Fee Related
-
2016
- 2016-05-06 JP JP2016093309A patent/JP2016188214A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20150241446A1 (en) | 2015-08-27 |
US8709433B2 (en) | 2014-04-29 |
EP2627669A4 (en) | 2014-04-09 |
PT2627669T (pt) | 2016-11-24 |
US9625473B2 (en) | 2017-04-18 |
MX2013003929A (es) | 2013-07-05 |
WO2012051106A1 (en) | 2012-04-19 |
EA025780B1 (ru) | 2017-01-30 |
EP2627669A1 (en) | 2013-08-21 |
US20140294899A1 (en) | 2014-10-02 |
ES2602977T3 (es) | 2017-02-23 |
JP2016188214A (ja) | 2016-11-04 |
AU2011313842A1 (en) | 2013-05-30 |
KR20140019296A (ko) | 2014-02-14 |
NZ609938A (en) | 2015-11-27 |
BR112013008573A2 (pt) | 2016-07-12 |
JP2013541010A (ja) | 2013-11-07 |
MX347871B (es) | 2017-05-16 |
NZ703122A (en) | 2016-06-24 |
AU2011313842B2 (en) | 2016-12-15 |
IL225118A (en) | 2017-10-31 |
PL2627669T3 (pl) | 2017-02-28 |
US20120121619A1 (en) | 2012-05-17 |
EP2627669B1 (en) | 2016-08-17 |
US9063153B2 (en) | 2015-06-23 |
CA2814500A1 (en) | 2012-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201390543A1 (ru) | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат | |
Sun et al. | Cytokine storm intervention in the early stages of COVID-19 pneumonia | |
Fang et al. | Obesity and immune status in children | |
WO2014058976A3 (en) | Biomarkers predictive for clinical response for glatiramer acetate | |
NZ598732A (en) | Dosage regimen for administering a cd19xcd3 bispecific antibody | |
NZ609493A (en) | Diagnosis and treatments relating to th2 inhibition | |
BR112012030625A2 (pt) | uso de inibidores de tirosina quinase de bruton (btk) | |
EA200801071A1 (ru) | Способы и композиции для применения в целях лечения пациентов с положительным по аутоантителам заболеванием | |
UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy | |
CL2008002886A1 (es) | Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende. | |
EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
IN2012DN06309A (ru) | ||
NZ590994A (en) | Anti il-7r antibodies treatment of autoimmune and inflammatory disease | |
ATE556717T1 (de) | Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus | |
MX2014005996A (es) | Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia. | |
Lin et al. | The unhealthy lifestyle factors associated with an increased risk of poor nutrition among the elderly population in China | |
Aktunc et al. | The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis | |
EP3974450A3 (en) | Biomarker | |
WO2010031749A9 (en) | Compositions and methods for detecting tlr3 | |
EA201491369A1 (ru) | Способ лечения сахарного диабета при помощи негликозилированного аполипопротеина a-iv | |
van Hooij et al. | BCG-induced immunity profiles in household contacts of leprosy patients differentiate between protection and disease | |
Schmid et al. | Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function | |
MX2009001070A (es) | Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. | |
Li et al. | Differential regulation of Tregs and Th17/Th1 cells by a sirolimus-based regimen might be dependent on STAT-signaling in renal transplant recipients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |